Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

South Korea To Donate H1N1 Flu Fighters to Estranged North On Friday

This article was originally published in PharmAsia News

Executive Summary

SEOUL - In a symbol of friendship and compassion toward the reclusive North Korea, leaders of South Korea's Unification Ministry said they will send the antiviral drugs Tamiflu and Relenza across the heavily militarized border on Friday to help the impoverished North prepare for the A/H1N1 pandemic

You may also be interested in...



South Korea Plans To Provide Tamiflu and Relenza To North Korea

SEOUL - With information on the spread of the A/H1N1 pandemic in North Korea closely guarded, the South Korean government is moving to supply the antiviral drugs Tamiflu and Relenza to workers in the North's Gaesung Industrial Zone as a gesture of compassion and reconciliation between the two Koreas

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel